Self-Pierce Riveting of Three Thin Sheets of Aluminum Alloy A5052 and 980 MPa Steel

Self-pierce riveting of three thin sheets of 980 MPa steel and 5052 aluminum alloy was performed to investigate the effect of sheet configuration on the deforming behaviors of the sheets and the rivet and joint strength. When the lower sheet was aluminum alloy, the joining range was relatively wide, i.e., the interlock hooking the rivet leg tended to be large. In the sheet configuration in which the upper and lower sheets were A5052 and the middle sheet was 980 MPa steel, the rivet leg spread out moderately and the joint without defects was obtained. In the lower 980 MPa steel sheet, fracture tended to occur due to the low ductility of the lower sheet, and the joining range was narrow with the small interlock although the three sheets were joined by an appropriate die shape. In joint strength of joined three sheets, fracture occurred in the lower-strength aluminum alloy sheet if interlocks of about 300 μm and 150 μm could be formed in the lower aluminum alloy sheet and 980 MPa steel sheet, respectively.     

髋关节假体体外磨损试验的应用及研究进展

体外磨损试验(ISO 14242)基于良好的实验室控制条件和操作规范模拟人体行走步态的关节承受载荷和运动角度范围,广泛用于比较髋关节假体不同材料、假体设计的耐磨损性能.本文基于体外磨损试验和临床磨损评价的研究文献,介绍体外磨损标准试验方法及其在髋关节设计开发中的应用,探讨体外磨损标准方法的局限、研究进展以及未来发展方向...     

超声引导下骶髂关节注射用于产后骶髂关节炎的治疗有效性研究

目的:研究超声引导下骶髂关节注射用于产后骶髂关节炎的治疗有效性.方法:选取2019年1月至2020年6月在本院接受治疗的60例产后骶髂关节炎患者,采用超声引导下骶髂关节注射治疗,观察患者治疗前后的晨僵时间、疼痛评分及治疗总有效率.结果:治疗后患者的晨僵时间明显缩短,疼痛评分显著下降(P<0.05).治疗后患者总有效率为...     

锁骨钩钢板固定治疗TossyⅢ型肩锁关节脱位的临床研究

目的:评价应用锁骨钩板治疗完全性肩锁关节脱位的临床疗效.方法:31例均为TossyⅢ型肩锁关节完全性脱位,应用锁骨钩板固定治疗.所有病例均直接修复断裂的肩锁韧带.结果:全部病例获得随访,随访6～18月,平均为12月.结果按karlsson标准进行评价,优良22例,满意9例,差0例.患者无感染,无金属内植物折断及松动,肩锁关节无再脱位.结论:锁骨钩钢板固定可靠,可以早期进行功能锻炼,是治疗完全性肩锁关节脱位的一种可靠的方法.     

骨与关节损伤治疗中存在的问题与对策

尽管骨关节损伤治疗已取得巨大进展,但仍存在许多问题,主要包括:对骨折治疗理念转变和微创外科概念的错误理解,对骨折治疗技术的不正确使用,忽视骨折分类方法和功能评定标准.正确的分析和解决这些问题会进一步促进创伤骨科临床实践和科研的进步.     

膝关节半月板及股骨髁软骨损伤关节镜下标准化分区法及其临床应用

目的 制定膝关节半月板及股骨髁软骨损伤标准化分区图,探讨其对膝关节镜手术病人病情评估和术后疗效评价的作用。方法 通过对186例膝关节镜手术患者术中膝关节分区图记录资料汇总分类,统计分析半月板及股骨髁软骨损伤部位。结果 186例病人中,膝关节损伤总数242膝,其中左膝关节损伤110膝（45．4％）,右膝损伤132膝（54．5％）。在192膝半月板损伤中,外侧半月板损伤116膝（60．4％）,内侧半月板损伤76膝（39．6％）。股骨髁软骨损伤75膝,内侧髁软骨损伤45膝（60％）,外侧髁软骨损伤30膝（40％）。半月板损伤的好发部位为6区（38膝）和2区（37膝）,股骨髁软骨损伤的多发部位为4区（20膝）、5区（21膝）。结论 外侧半月板损伤多于内侧半月板,其体部和后角为损伤好发部位。股骨髁内侧区软骨损伤多见。膝关节标准化分区图对膝关节镜手术中病情的评估和术后疗效评价具有重要辅助作用。     

Resveratrol alleviates temporomandibular joint inflammatory pain by recovering disturbed gut microbiota

Patients with temporomandibular disorders (TMDs) often experience persistent facial pain. However, the treatment of TMD pain is still inadequate. In recent years, the disturbance of gut microbiota has been shown to play an important role in the pathogenesis of different neurological diseases including chronic pain. In the present study, we investigated the involvement of gut microbiota in the development of temporomandibular joint (TMJ) inflammation. Intra-temporomandibular joint injection of complete Freund's adjuvant (CFA) was employed to induce TMJ inflammation. Resveratrol (RSV), a natural bioactive compound with anti-inflammatory property, was used to treat the CFA-induced TMJ inflammation. We observed that CFA injection not only induces persistent joint pain, but also causes the reduction of short-chain fatty acids (SCFAs, including acetic acid, propionic acid and butyric acid) in the gut as well as decreases relevant gut bacteria Bacteroidetes and Lachnospiraceae. Interestingly, systemic administration of RSV (i.p.) dose-dependently inhibits CFA-induced TMJ inflammation, reverses CFA-caused reduction of SCFAs and these gut bacteria. Moreover, CFA injection causes blood–brain barrier (BBB) leakage, activates microglia and enhances tumor necrosis factor alpha (TNFα) release in the spinal trigeminal nucleus caudalis (Sp5C). The RSV treatment restores the BBB integrity, inhibits microglial activation and decreases the release of TNFα in the Sp5C. Furthermore, fecal microbiota transplantation with feces from RSV-treated mice significantly diminishes the CFA-induced TMJ inflammation. Taken together, our results suggest that gut microbiome perturbation is critical for the development of TMJ inflammation and that recovering gut microbiome to normal levels could be a new therapeutic approach for treating such pain.     

Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments

Osteoarthritis results in chronic pain and loss of function. Proinflammatory cytokines create both osteoarthritis pathology and pain. Current treatments are poorly effective, have significant side effects, and have not targeted the cytokines central to osteoarthritis development and maintenance. Interleukin-10 is an anti-inflammatory cytokine that potently and broadly suppresses proinflammatory cytokine activity. However, interleukin-10 protein has a short half-life in vivo and poor joint permeability. For sustained IL-10 activity, we developed a plasmid DNA-based therapy that expresses a long-acting human interleukin-10 variant (hIL-10var). Here, we describe the 6-month GLP toxicology study of this therapy. Intra-articular injections of hIL-10var pDNA into canine stifle joints up to 1.5 mg bilaterally were well-tolerated and without pathologic findings. This represents the first long-term toxicologic assessment of intra-articular pDNA therapy. We also report results of a small double-blind, placebo-controlled study of the effect of intra-articular hIL-10var pDNA on pain measures in companion (pet) dogs with naturally occurring osteoarthritis. This human IL-10-based targeted therapy reduced pain measures in the dogs, based on veterinary and owner ratings, without any adverse findings. These results with hIL-10var pDNA therapy, well-tolerated and without toxicologic effects, establish the basis for clinical trials of a new class of safe and effective therapies for OA.     

Running gait biomechanics in female runners with sacroiliac joint pain

[Purpose] To identify running gait biomechanics associated with sacroiliac (SI) joint pain in female runners compared to healthy controls. [Participants and Methods] In this case-control study, treadmill running gait biomechanics of female runners diagnosed SI joint pain, (by ultrasound-guided diagnostic SI joint injection and/or ≥2 positive SI physical exam maneuvers) were compared with age, height, mass, and BMI matched healthy female runners. Sagittal and coronal plane treadmill running video angles were measured and compared. [Results] Eighteen female runners with SI pain, and 63 matched controls, were analyzed. There was no difference in age, height, mass, or BMI between groups. At the point of initial contact, runners with SI joint pain demonstrated less knee flexion, greater tibial overstride, and greater ankle dorsiflexion, compared to controls. In midstance, runners with SI pain had greater contralateral pelvic drop compared to controls. For unilateral SI joint pain cases (N=15), greater contralateral pelvic drop was observed when loading their affected side compared to the unaffected side. [Conclusion] Female runners with SI joint pain demonstrated greater contralateral pelvic drop during midstance phase; along with less knee flexion, greater “tibial overstride”, and greater ankle dorsiflexion at initial contact compared to controls.